Equities

Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)32.16
  • Today's Change-2.55 / -7.35%
  • Shares traded1.02m
  • 1 Year change+39.16%
  • Beta0.8162
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments311174186
Total Receivables, Net180183106
Total Inventory324717
Prepaid expenses12175.85
Other current assets, total2.730.060.03
Total current assets538420316
Property, plant & equipment, net222627
Goodwill, net134134--
Intangibles, net422567269
Long term investments------
Note receivable - long term------
Other long term assets0.830.100.09
Total assets1,1431,174692
LIABILITIES
Accounts payable8.693.494.19
Accrued expenses259263224
Notes payable/short-term debt000
Current portion long-term debt/capital leases18316348
Other current liabilities, total7.154.353.19
Total current liabilities458434280
Total long term debt484538202
Total debt667701250
Deferred income tax------
Minority interest------
Other liabilities, total6.127.117.95
Total liabilities948979489
SHAREHOLDERS EQUITY
Common stock0.040.040.04
Additional paid-in capital566538502
Retained earnings (accumulated deficit)(233)(281)(256)
Treasury stock - common(137)(62)(43)
Unrealized gain (loss)------
Other equity, total0.01----
Total equity195195203
Total liabilities & shareholders' equity1,1431,174692
Total common shares outstanding323434
Treasury shares - common primary issue6.323.242.15
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.